Hodgkin lymphoma

A review and update on recent progress

Research output: Contribution to journalReview article

Abstract

Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long-term treatment toxicities. CA Cancer J Clin 2018;68:116-132.

Original languageEnglish (US)
Pages (from-to)116-132
Number of pages17
JournalCA Cancer Journal for Clinicians
Volume68
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Hodgkin Disease
Hematopoietic Stem Cell Transplantation
Combination Drug Therapy
Therapeutics
Reed-Sternberg Cells
Dacarbazine
Vinblastine
Bleomycin
Hematologic Neoplasms
Secondary Prevention
Doxorubicin
Tissue Donors
Radiation
Antibodies
Pharmaceutical Preparations
Neoplasms

Keywords

  • allogeneic stem cell transplantation
  • antibody-drug conjugate
  • brentuximab
  • Hodgkin lymphoma
  • immunotherapy
  • positron emission tomography (PET)-adapted therapy
  • programmed death 1 (PD-1) inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hodgkin lymphoma : A review and update on recent progress. / Shanbhag, Satish P; Ambinder, Richard F.

In: CA Cancer Journal for Clinicians, Vol. 68, No. 2, 01.03.2018, p. 116-132.

Research output: Contribution to journalReview article

@article{de586355e9184d7fbaad758b43f99432,
title = "Hodgkin lymphoma: A review and update on recent progress",
abstract = "Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long-term treatment toxicities. CA Cancer J Clin 2018;68:116-132.",
keywords = "allogeneic stem cell transplantation, antibody-drug conjugate, brentuximab, Hodgkin lymphoma, immunotherapy, positron emission tomography (PET)-adapted therapy, programmed death 1 (PD-1) inhibitor",
author = "Shanbhag, {Satish P} and Ambinder, {Richard F}",
year = "2018",
month = "3",
day = "1",
doi = "10.3322/caac.21438",
language = "English (US)",
volume = "68",
pages = "116--132",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Hodgkin lymphoma

T2 - A review and update on recent progress

AU - Shanbhag, Satish P

AU - Ambinder, Richard F

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long-term treatment toxicities. CA Cancer J Clin 2018;68:116-132.

AB - Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. Future research will look to integrate novel strategies into earlier lines of therapy to improve the HL cure rate and minimize long-term treatment toxicities. CA Cancer J Clin 2018;68:116-132.

KW - allogeneic stem cell transplantation

KW - antibody-drug conjugate

KW - brentuximab

KW - Hodgkin lymphoma

KW - immunotherapy

KW - positron emission tomography (PET)-adapted therapy

KW - programmed death 1 (PD-1) inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85043348659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043348659&partnerID=8YFLogxK

U2 - 10.3322/caac.21438

DO - 10.3322/caac.21438

M3 - Review article

VL - 68

SP - 116

EP - 132

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

SN - 0007-9235

IS - 2

ER -